Eli Lilly and Company $LLY Shares Purchased by Robertson Stephens Wealth Management LLC

Key Points

• Robertson Stephens Wealth Management LLC increased its stake in Eli Lilly by 21.4%, holding 7,253 shares valued at approximately $5.65 million.
• Eli Lilly's recent earnings report showed a significant 37.6% increase in revenue year-over-year, with an EPS of $6.31, beating expectations by $0.72.
• Despite positive financial results, Eli Lilly's stock recently declined by 2.6%, and analysts have varied target prices ranging from $700.00 to $1,050.00.

Robertson Stephens Wealth Management LLC boosted its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 21.4% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 7,253 shares of the company's stock after acquiring an additional 1,278 shares during the quarter. Robertson Stephens Wealth Management LLC's holdings in Eli Lilly and Company were worth $5,654,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in LLY. Precedent Wealth Partners LLC boosted its stake in Eli Lilly and Company by 15.3% during the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company's stock worth $229,000 after purchasing an additional 39 shares during the last quarter. Capital Advisors Inc. OK boosted its stake in Eli Lilly and Company by 6.8% during the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company's stock worth $5,260,000 after purchasing an additional 429 shares during the last quarter. Family CFO Inc acquired a new stake in Eli Lilly and Company during the 2nd quarter worth $54,000. Duquesne Family Office LLC boosted its stake in Eli Lilly and Company by 52.5% during the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock worth $78,321,000 after purchasing an additional 32,640 shares during the last quarter. Finally, Corient IA LLC acquired a new stake in Eli Lilly and Company during the 1st quarter worth $570,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Down 2.6%

NYSE LLY opened at $833.08 on Friday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $937.00. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The business's fifty day simple moving average is $742.42 and its 200-day simple moving average is $766.36. The firm has a market cap of $788.47 billion, a PE ratio of 54.45, a P/E/G ratio of 1.19 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter in the prior year, the company posted $3.92 earnings per share. Eli Lilly and Company's revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

LLY has been the topic of several recent research reports. JPMorgan Chase & Co. lowered their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a research note on Tuesday, September 16th. UBS Group lowered their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Eli Lilly and Company in a research note on Wednesday. Berenberg Bank reiterated a "hold" rating and set a $830.00 price target (down previously from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Finally, Daiwa Capital Markets lowered Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target on the stock. in a report on Sunday, August 17th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $948.56.

Insider Buying and Selling

In related news, Director Jamere Jackson bought 200 shares of the firm's stock in a transaction on Friday, August 8th. The shares were bought at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the transaction, the director directly owned 9,402 shares of the company's stock, valued at $6,013,143.12. This represents a 2.17% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Daniel Skovronsky bought 1,000 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was bought at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the transaction, the executive vice president directly owned 137,660 shares of the company's stock, valued at $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 4,514 shares of company stock valued at $2,894,841 over the last three months. Company insiders own 0.13% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.